Parkin Unveiled: Paving the Way for Breakthroughs in Neurodegenerative Research

By: Derrick Padykula and Isabelle Wentzel Hallmark of Neurodegeneration Diving into the complex world of neurodegeneration unveils the long road marked by the gradual decline of neuronal cells, ultimately leading to cell death. In Parkinson’s disease (PD) and Alzheimer’s disease (AD), the accumulation of aggregated proteins and dysfunctional mitochondria is what contributes to the demise of […]
LifeSensors is invited to speak at Discovery on Target 2023 – Breakthrough Molecules with Unique Molecular Glue & PROTAC Platform

MALVERN, Pa., SEP 21, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at the 21st annual Discovery on Target 2023. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting new information, and answering questions regarding PROTACs, […]
LifeSensors is Partnering at BIO International Convention 2023

MALVERN, PA., May 30, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTACs, molecular glues, and neurodegeneration diagnostics will disclose direct methods to detect PROTAC & molecular glue mediated ubiquitination drug targets at BIO this year in Boston, MA, June 5-8, 2023. Current methods of PROTAC & Molecular Glue discovery are time consuming, […]
Profiling E3 ligase compounds and the Implications in Drug Discovery

By: Abdul Haseeb, Ph.D. Drugging the Undruggable Tremendous progress in genomics, transcriptomics and proteomics has led to the discovery of thousands of new drivers of disease, but drug discovery is still catching up to these new potential drug targets because most of these new players are intractable to traditional pharmacological targeting. Traditional small molecule […]
Accelerating PROTAC drug discovery: Establishing a Relationship Between Ubiquitination and Target Protein Degradation

MALVERN, Pa., SEP 1, 2022 – LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glues, and neurodegeneration diagnostics, is pleased to announce that Lifesensors has published a seminal paper: Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation. This paper is published in the Biochemical and Biophysical […]
A New Generation of TUBEs

Dear Colleagues, Deciphering the Ubiquitin Code is the first step in utilizing the Ubiquitin Proteasome System (UPS) to drug the so-called undruggable targets. LifeSensors is proud to present a new technology which will allow for much more precise and accurate targeting of the UPS. The new K48 TUBE HF was developed to show enhanced selectivity […]